1. Is the EuroSCORE II reliable in surgical mitral valve repair? A single-centre validation study
- Author
-
Alessandro Verzini, Roberta Meneghin, Guido Ascione, Stefania Ruggeri, Michele De Bonis, Nicola Buzzatti, Ottavio Alfieri, Anna Mara Scandroglio, Fabrizio Monaco, Elisabetta Lapenna, Davide Carino, Eustachio Agricola, Paolo Denti, Benedetto Del Forno, Alessandro Castiglioni, Carino, Davide, Denti, Paolo, Ascione, Guido, Del Forno, Benedetto, Lapenna, Elisabetta, Ruggeri, Stefania, Agricola, Eustachio, Buzzatti, Nicola, Verzini, Alessandro, Meneghin, Roberta, Scandroglio, Anna Mara, Monaco, Fabrizio, Castiglioni, Alessandro, Alfieri, Ottavio, and De Bonis, Michele
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Validation study ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Risk Assessment ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Euroscore ii ,Risk Factors ,Risks scores ,Internal medicine ,Humans ,Medicine ,Hospital Mortality ,Cardiac Surgical Procedures ,Retrospective Studies ,Mitral valve repair ,Mitral regurgitation ,Receiver operating characteristic ,business.industry ,Area under the curve ,General Medicine ,EuroSCORE II ,Degenerative mitral regurgitation ,Cardiac surgery ,ROC Curve ,Secondary mitral regurgitation ,030228 respiratory system ,Brier score ,Cardiology ,Mitral Valve ,Surgery ,Cardiology and Cardiovascular Medicine ,business - Abstract
OBJECTIVES The EuroSCORE II is widely used to predict 30-day mortality in patients undergoing open and transcatheter cardiac surgery. The aim of this study is to evaluate the discriminatory ability of the EuroSCORE II in predicting 30-day mortality in a large cohort of patients undergoing surgical mitral valve repair in a high-volume centre. METHODS A retrospective review of our institutional database was carried on to find all patients who underwent mitral valve repair in our department from January 2012 to December 2019. Discrimination of the EuroSCORE II was assessed using receiver operating characteristic curves. The maximum Youden’s Index was employed to define the optimal cut-point. Calibration was assessed by generating calibration plot that visually compares the predicted mortality with the observed mortality. Calibration was also tested with the Hosmer–Lemeshow goodness-of-fit test. Finally, the accuracy of the models was tested calculating the Brier score. RESULTS A total of 2645 patients were identified, and the median EuroSCORE II was 1.3% (0.6–2.0%). In patients with degenerative mitral regurgitation (MR), the EuroSCORE II showed low discrimination (area under the curve 0.68), low accuracy (Brier score 0.27) and low calibration with overestimation of the 30-day mortality. In patients with secondary MR, the EuroSCORE II showed a good overall performance estimating the 30-day mortality with good discrimination (area under the curve 0.88), good accuracy (Brier score 0.003) and good calibration. CONCLUSIONS In patients with degenerative MR operated on in a high-volume centre with a high level of expertise in mitral valve repair, the EuroSCORE II significantly overestimates the 30-day mortality.
- Published
- 2020
- Full Text
- View/download PDF